Device Trial Radar · NCT07907055
PAUL® Glaucoma Implant Safety and Effectiveness Study
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
65
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
May 1, 2028
Study completion Aug 1, 2028
Sponsor
- Lead sponsor
- Clinical Research Consultants, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 30, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective, multicenter clinical study is designed to evaluate the safety and effectiveness of the PAUL® Glaucoma Implant in adult patients with refractory glaucoma. Effectiveness will be assessed by measuring the reduction in intraocular pressure (IOP). Study results will support regulatory submissions to the U.S. Food and Drug Administration (FDA) and may also be used to support regulatory submissions and postmarketing surveillance activities in other countries.
Conditions
- Refractory Glaucoma
Interventions
PAUL® Glaucoma ImplantDevice
The PAUL® Glaucoma Implant is an aqueous drainage device surgically implanted to facilitate aqueous humor drainage and reduce intraocular pressure in patients with refractory glaucoma.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects Achieving ≥20% Reduction in Mean Diurnal Intraocular Pressure (DIOP)Time frame: Baseline to 12 months postoperatively
3 more outcomes with a free account
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.